• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

EE392 Cost-Effectiveness Analysis of Atrial Fibrillation Screening for a 50 –65-Year-Old Population With Elevated Stroke Risk
Atrial fibrillation (AF) is one of the main risk factors for strokes. European guidelines recommend screening measures to detect AF for the age group above 65 years. Cost-effectiveness of a telemetric AF-detection method (Preventicus Heartbeats) was demonstrated for the age group above 65 years for Germany. Below 65 years screening is only recommended with presence of risk factors, usually assessed by CHA2DS2-VASc score. This analysis examines the cost-effectiveness of telemetric AF-screening for the population aged 50-65 years in Germany with CHA2DS2-VASc score of minimum 1 (men) or minimum 2 (women).
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: S Wahler, A M üller, R Birkemeyer, JM von der Schulenburg Source Type: research

A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany
ConclusionsThe modelling demonstrates the health benefits and economic effects of an implementation of a systematic screening on AF with “Preventicus Heartbeats”, given the perspective of the German payer, the statutory health care system.
Source: Health Economics Review - June 8, 2020 Category: International Medicine & Public Health Source Type: research

Effects of Improved Detection And Treatment of Atrial Fibrillation On Burden of Disease Caused By Stroke In Germany
Atrial fibrillation (AF) is a major risk factor for stroke with a prevalence of 1-2% of the general population. Patients with non-valvular AF show a 4 to5 times higher risk of stroke. According to a German registry study, AF goes undetected in one third of affected patients. Even if correctly diagnosed, AF is not always treated with oral anti-coagulants (OAC) according to treatment guidelines. For Germany, the estimated proportion of patients actually treated with OAC among all eligible AF-patients ranges from 38% to 83%.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: H Nolting, B Deckenbach, K Zich Source Type: research

Long-Term Health Benefits of Treating Non-Valvular Atrial Fibrillation with Apixaban Versus Vitamin K Antagonists In Germany: A Population-Based Modelling Study
Patients with non-valvular atrial fibrillation (NVAF) are five times more likely to suffer a stroke, resulting in enormous personal, social and economic costs. For more than 50 years, vitamin K antagonists (VKAs) have been the primary medication for stroke prevention. Nevertheless, VKA therapy requires frequent monitoring, is limited by a narrow therapeutic window and is associated with an increased risk of bleeding. Apixaban, a non-vitamin K oral anticoagulant (NOAC), has shown superior efficacy and reduced risk of major bleeding compared to VKA in the ARISTOTLE trial.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: M Mueller, S Himmler, E Basic, E Hradetzky Source Type: research